ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 1,250 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $85.36, for a total transaction of $106,700.00. Following the completion of the sale, the chief financial officer now directly owns 79,572 shares of the company’s stock, valued at approximately $6,792,265.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Brett Sandercock also recently made the following trade(s):
- On Wednesday, November 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The stock was sold at an average price of $84.50, for a total transaction of $105,625.00.
- On Monday, October 2nd, Brett Sandercock sold 1,250 shares of ResMed stock. The stock was sold at an average price of $77.05, for a total transaction of $96,312.50.
ResMed Inc. (RMD) opened at $83.57 on Tuesday. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50. ResMed Inc. has a fifty-two week low of $58.71 and a fifty-two week high of $87.81. The company has a market cap of $11,955.40, a P/E ratio of 29.35, a PEG ratio of 1.87 and a beta of 0.78.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Shareholders of record on Thursday, November 9th will be issued a dividend of $0.35 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $1.40 dividend on an annualized basis and a yield of 1.68%. ResMed’s dividend payout ratio (DPR) is presently 56.68%.
RMD has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of ResMed from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a report on Thursday, October 12th. BMO Capital Markets upped their price objective on shares of ResMed from $70.00 to $74.00 and gave the stock a “market perform” rating in a report on Friday, October 27th. Credit Suisse Group lowered shares of ResMed from an “outperform” rating to a “neutral” rating in a report on Tuesday, August 8th. J P Morgan Chase & Co upped their price objective on shares of ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a report on Monday, October 30th. Finally, Northland Securities restated a “sell” rating and issued a $55.00 price objective on shares of ResMed in a report on Friday, October 27th. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $67.57.
A number of institutional investors have recently added to or reduced their stakes in the business. Visionary Asset Management Inc. acquired a new stake in ResMed during the 3rd quarter worth approximately $214,000. Crestwood Advisors Group LLC lifted its holdings in ResMed by 1.1% during the 3rd quarter. Crestwood Advisors Group LLC now owns 212,264 shares of the medical equipment provider’s stock worth $16,336,000 after buying an additional 2,375 shares in the last quarter. Wealthsource Partners LLC lifted its holdings in ResMed by 17.8% during the 3rd quarter. Wealthsource Partners LLC now owns 7,150 shares of the medical equipment provider’s stock worth $550,000 after buying an additional 1,080 shares in the last quarter. Coastline Trust Co lifted its holdings in ResMed by 39.4% during the 3rd quarter. Coastline Trust Co now owns 14,615 shares of the medical equipment provider’s stock worth $1,125,000 after buying an additional 4,130 shares in the last quarter. Finally, IFM Investors Pty Ltd acquired a new stake in ResMed during the 3rd quarter worth approximately $341,000. Institutional investors own 62.02% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “ResMed Inc. (RMD) CFO Brett Sandercock Sells 1,250 Shares of Stock” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/05/resmed-inc-rmd-cfo-brett-sandercock-sells-1250-shares-of-stock.html.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
What are top analysts saying about ResMed Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ResMed Inc. and related companies.